Filter posts

In Speaker Pelosi’s Extreme Drug Pricing Bill, Funding for NIH is MIA

Supporters of Speaker Pelosi’s extreme drug pricing bill (H.R. 3) want us to believe that …

The Pelosi Plan and "Me Too" Drugs

Supporters of Speaker Pelosi’s drug pricing plan (H.R. 3) claim the bill will discourage the …

Discussing a “Patient-Centered” Approach at BIO 2019

Placing patients at the center of everything the biotech industry stands for is a personal …

The Empty Promise of “Safe” Drug Importation

For years, BIO has been urging both state and federal policymakers to adopt responsible solutions …

Insurers Shift Costs and Facts

As health insurance companies begin setting rates for 2019, many consumers are once again faced …

ICER Comes Under Renewed Scrutiny

As we enter a new and exciting era of medicine, there is an important question …

#BIOCEO18: A Bright Future

“A transformative year in medicine.” That’s how BIO President and CEO Jim Greenwood recently described …

Here We Go Again (But In a Good Way)

“We achieved the lowest drug trend since we began measuring drug trend data in 1993.” …

Five Questions for the Senate Hearing on Prescription Drugs

On Tuesday, the Senate Committee on Health, Education, Labor, and Pensions will hold its third …

What's Driving Health Care Spending? Hint: Not Drug Costs.

With health care costs an important concern for many Americans, a common misperception is the …